CN119300831A - 含有特力利汀的制剂 - Google Patents

含有特力利汀的制剂 Download PDF

Info

Publication number
CN119300831A
CN119300831A CN202480002678.5A CN202480002678A CN119300831A CN 119300831 A CN119300831 A CN 119300831A CN 202480002678 A CN202480002678 A CN 202480002678A CN 119300831 A CN119300831 A CN 119300831A
Authority
CN
China
Prior art keywords
telithromycin
acid
teneligliptin
preparation containing
reference example
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480002678.5A
Other languages
English (en)
Chinese (zh)
Inventor
西村卓朗
丰田睛大
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sawai Pharmaceutical Co Ltd
Original Assignee
Sawai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sawai Pharmaceutical Co Ltd filed Critical Sawai Pharmaceutical Co Ltd
Publication of CN119300831A publication Critical patent/CN119300831A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202480002678.5A 2023-05-10 2024-04-11 含有特力利汀的制剂 Pending CN119300831A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023-078027 2023-05-10
JP2023078027 2023-05-10
PCT/JP2024/014708 WO2024232216A1 (ja) 2023-05-10 2024-04-11 テネリグリプチン含有製剤

Publications (1)

Publication Number Publication Date
CN119300831A true CN119300831A (zh) 2025-01-10

Family

ID=93430149

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480002678.5A Pending CN119300831A (zh) 2023-05-10 2024-04-11 含有特力利汀的制剂

Country Status (4)

Country Link
JP (1) JP7799904B2 (https=)
CN (1) CN119300831A (https=)
TW (1) TWI896097B (https=)
WO (1) WO2024232216A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7117975B2 (ja) * 2018-10-31 2022-08-15 沢井製薬株式会社 テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
WO2020209350A1 (ja) 2019-04-12 2020-10-15 田辺三菱製薬株式会社 糖尿病治療用口腔内速崩壊錠
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物
JP2023156269A (ja) 2022-04-12 2023-10-24 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Also Published As

Publication number Publication date
TW202444369A (zh) 2024-11-16
JPWO2024232216A1 (https=) 2024-11-14
JP7799904B2 (ja) 2026-01-15
WO2024232216A1 (ja) 2024-11-14
TWI896097B (zh) 2025-09-01

Similar Documents

Publication Publication Date Title
US8877238B2 (en) Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
JP6423133B1 (ja) エスシタロプラム医薬組成物
WO2013179307A2 (en) Stabilized pharmaceutical compositions of saxagliptin
JP2019031576A (ja) 非晶質体ソリフェナシン及び抗酸化剤を含有する固形製剤
EP4008317A1 (en) Solid pharmaceutical formulations of amorphous dapagliflozin
KR20170055211A (ko) 무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법
US20120035177A1 (en) Tablet formulation for p38 inhibitor and method
EP2101742B1 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
CN119300831A (zh) 含有特力利汀的制剂
JP7518316B1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
JP7102200B2 (ja) コハク酸ソリフェナシン含有固形医薬組成物
US20260102499A1 (en) Compositions with reduced nitrosamine impurities
WO2013190151A1 (en) Pharmaceutical composition comprising fingolimod
KR20160014619A (ko) 공-결정체 형태로 아고멜라틴을 포함하는 아고멜라틴 제형
WO2024171708A1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
EP3505158A1 (en) Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
KR101406265B1 (ko) 안정성이 개선된 프라미펙솔을 함유하는 약제학적 조성물 및 이의 제조방법
KR101641319B1 (ko) 안정성이 개선된 에카베트와 라니티딘의 복합 제제
CN116322653B (zh) 包括酞嗪酮衍生物的药物组合物
KR20180003340A (ko) 무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법
EP3842035A1 (en) Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules
WO2012060787A1 (en) Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
TW200418486A (en) Solid preparation
EP2996681B1 (en) Pharmaceutical composition comprising fingolimod
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication